Wendel Naumann, MD:HR [homologous recombination]-proficient versus HR-deficient is a marker for biologic aggressiveness of the tumor and response to chemotherapy.
We know that HR-proficient tumors relate to poor prognosis with ovarian cancer. These patients don’t respond to chemotherapy as well. And while they got a benefit for maintenance PARP [poly ADP ribose polymerase] inhibition, that benefit was somewhat limited. We had an improvement in progression-free survival of only about 2 to 3 months. Now having said that, there is a group of those patients who get a significant benefit for a long period. And I think we don’t do a good job of separating those patients out.
For patients who are HR-deficient, I think that the PARP inhibitors are an excellent choice for maintenance therapy. We know patients are going to get a very good benefit, very similar to the patients with theBRCAmutations.
Niraparib has been shown in the PRIMA trial to benefit all patients after chemotherapy and surgery. The amount of benefit is based on the mutation or the HR deficiency. The more HR-deficient these patients are, the better the benefit that they get from the maintenance niraparib.
Niraparib basically prevents DNA repair. Cells that are HR-deficient have a hard time repairing the DNA damage because the homologous repair mechanism is broken. And if we can inhibit PARP, that prevents these cells from repairing the DNA damage. And therefore there is a selective benefit to this that is directed toward the cancer cells and not toward the normal cells since the normal cells retain some of their homologous repair mechanism.
Transcript edited for clarity.
Case: A 54-Year-Old Female With Ovarian Cancer
H & P
KEYNOTE-A18 Supports Pembrolizumab and CRT as New Standard in High-Risk Cervical Cancer
September 14th 2024Pembrolizumab combined with chemoradiotherapy followed by pembrolizumab monotherapy significantly improved survival compared to chemoradiotherapy alone in patients with high-risk locally advanced cervical cancer.
Read More
Pembrolizumab Plus CCRT Scores in East Asian Subgroup With Cervical Cancer
September 9th 2024Pembrolizumab plus concurrent chemoradiotherapy demonstrated a higher progression-free survival rate than placebo plus concurrent chemoradiotherapy for patients with high-risk, locally advanced cervical cancer in the East Asia subgroup of the phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study.
Read More